Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care.
age-related macular degeneration
central serous chorioretinopathy
choroidal haemangioma
photodynamic therapy
polypoidal choroidal vasculopathy
verteporfin
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
11
02
2022
accepted:
23
03
2022
pubmed:
8
4
2022
medline:
12
10
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
Since July 2021, a worldwide shortage of verteporfin (Visudyne®) occurred: an essential medicine required for photodynamic therapy (PDT). PDT with verteporfin has a broad range of indications in ophthalmology, including chronic central serous chorioretinopathy, polypoidal choroidal vasculopathy and choroidal haemangioma. For these disorders, PDT is either the first-choice treatment or regarded as a major treatment option. A questionnaire was sent to key opinion leaders in the field of medical retina throughout the world, to assess the role of PDT in their country and the effects of the shortage of verteporfin. In addition, information on the application of alternative treatments during shortage of verteporfin was obtained, to further assess the impact of the shortage. Our questionnaire indicated that the shortage of verteporfin had a major impact on ophthalmic care worldwide and was regarded to be a serious problem by most of our respondents. However, even though there is ample evidence to support the use of PDT in several chorioretinal diseases, we found notable differences in its use in normal patient care throughout the world. Various alternative management strategies were noted during the verteporfin shortage, including lowering the dose of verteporfin per patient, the use of alternative treatment strategies and the use of a centralized system for allocating the remaining ampoules of verteporfin in some countries. The shortage of verteporfin has had a large effect on the care of ophthalmic patients across the world and may have resulted in significant and irreversible vision loss. Mitigation strategies should be developed in consultation with all stakeholders to avoid future medication shortages of verteporfin and other unique ophthalmic medications. These strategies may include mandatory stock keeping, compulsory licensing to an alternative manufacturer or incentivizing the development of competition, for example through novel public-private partnerships.
Identifiants
pubmed: 35388619
doi: 10.1111/aos.15148
pmc: PMC9790583
doi:
Substances chimiques
Photosensitizing Agents
0
Porphyrins
0
Verteporfin
0X9PA28K43
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1522-e1532Subventions
Organisme : The Nationale Postcode Loterij
Informations de copyright
© 2022 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
Prog Retin Eye Res. 2022 Jan;86:100973
pubmed: 34029721
Ophthalmology. 2009 Jan;116(1):100-105.e1
pubmed: 18973950
Lancet. 2020 Jan 25;395(10220):294-303
pubmed: 31982075
Photodiagnosis Photodyn Ther. 2020 Mar;29:101665
pubmed: 31978565
Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):260-268
pubmed: 32332215
J Clin Med. 2019 Mar 25;8(3):
pubmed: 30934605
Prog Retin Eye Res. 2021 Sep;84:100955
pubmed: 33716160
Br J Ophthalmol. 2021 Jun;105(6):794-799
pubmed: 32675064
Med Hist. 1982 Apr;26(2):179-82
pubmed: 7047941
Am J Ophthalmol. 2012 Mar;153(3):504-514.e1
pubmed: 22078902
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Am J Ophthalmol. 2019 Sep;205:1-10
pubmed: 30951686
Retina. 2018 Apr;38(4):725-730
pubmed: 28333878
Retina. 2012 Sep;32(8):1453-64
pubmed: 22426346
Graefes Arch Clin Exp Ophthalmol. 2021 Feb;259(2):351-361
pubmed: 32812132
Surv Ophthalmol. 2011 Jan-Feb;56(1):68-85
pubmed: 21074819
J Photochem Photobiol B. 1993 Sep;20(1):5-22
pubmed: 8229469
Am J Ophthalmol. 2022 Jan;233:101-110
pubmed: 34214454
JAMA Ophthalmol. 2018 Jul 1;136(7):786-793
pubmed: 29801063
Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
J Pharm Policy Pract. 2017 Jun 28;10:19
pubmed: 28670455
Dermatol Surg. 2016 Jul;42(7):804-27
pubmed: 27336945
Ophthalmology. 2021 Mar;128(3):443-452
pubmed: 32795496
Lancet. 1972 Dec 2;2(7788):1175-7
pubmed: 4117595
Acta Ophthalmol. 2010 Dec;88(8):e334-40
pubmed: 20946329
Ophthalmology. 2009 Jan;116(1):57-65.e5
pubmed: 19118696
JAMA Ophthalmol. 2020 Sep 1;138(9):935-942
pubmed: 32672800
Br J Ophthalmol. 2005 Jan;89(1):113-9
pubmed: 15615758
J Law Med Ethics. 2020 Dec;48(4):789-795
pubmed: 33404340
Biomed Pharmacother. 2018 Oct;106:1098-1107
pubmed: 30119176
Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):1023-41
pubmed: 22762303
Future Oncol. 2010 Jun;6(6):929-40
pubmed: 20528231
Prog Retin Eye Res. 2019 Nov;73:100770
pubmed: 31319157
Arch Ophthalmol. 1999 Oct;117(10):1329-45
pubmed: 10532441
Clin Exp Ophthalmol. 2018 Mar;46(2):189-200
pubmed: 29178419
Br J Ophthalmol. 2017 May;101(5):587-590
pubmed: 27539091
Clin Ophthalmol. 2018 Oct 24;12:2167-2176
pubmed: 30498331
Arch Ophthalmol. 1989 Sep;107(9):1338-42
pubmed: 2783066
Ophthalmol Ther. 2020 Jun;9(2):329-342
pubmed: 32279234
Ophthalmology. 2018 Oct;125(10):1547-1555
pubmed: 29776672
Pharm Pat Anal. 2017 Jul;6(4):161-170
pubmed: 28696178
Photodiagnosis Photodyn Ther. 2009 Mar;6(1):3-11
pubmed: 19447366
Br J Cancer. 1998 Mar;77(6):1021-4
pubmed: 9528851
J Ophthalmic Vis Res. 2015 Jul-Sep;10(3):320-8
pubmed: 26730320
Ophthalmology. 2002 Dec;109(12):2284-94
pubmed: 12466172
Prog Retin Eye Res. 2016 Jul;53:107-139
pubmed: 27094371
Proc Soc Exp Biol Med. 1948 Jul-Aug;68(3):640
pubmed: 18884315
Am J Ophthalmol. 2020 Aug;216:80-89
pubmed: 32289294
Blood Cells Mol Dis. 2010 Jan 15;44(1):41-7
pubmed: 19804996